PAVmed Inc PAVM.OQ PAVM.O is expected to show a rise in quarterly revenue when it reports results on November 13 for the period ending September 30 2024
The New York City-based company is expected to report a 38.2% increase in revenue to $1.093 million from $791 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for PAVmed Inc is for earnings of $1.98 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for PAVmed Inc is $4.00, above its last closing price of $1.12.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -1.48 | -1.45 | -1.19 | Beat | 18.1 |
Mar. 31 2024 | -1.77 | -1.67 | -2.62 | Missed | -56.6 |
Dec. 31 2023 | -1.47 | -1.89 | -1.81 | Beat | 4.2 |
Sep. 30 2023 | -2.04 | -2.05 | -2.40 | Missed | -17.1 |
Jun. 30 2023 | -2.84 | -2.85 | -2.10 | Beat | 26.3 |
Mar. 31 2023 | -3.11 | -3.10 | -2.85 | Beat | 8.1 |
Dec. 31 2022 | -3.84 | -3.80 | -3.45 | Beat | 9.2 |
Sep. 30 2022 | -3.98 | -3.97 | -4.35 | Missed | -9.4 |
This summary was machine generated November 12 at 03:49 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments